Combined MAPK targeting via cobimetinib (MEK1/2 inhibitor) and dabrafenib (BRAF inhibitor), a clinical approach used to abrogate rapid acquired resistance to MAPK targeting resulted in deeper and more prolonged responses than monotherapy AZD6244 in BRAF PTEN melanoma (Supplementary Fig. S4A). Here, MAP2K1 is linked to melanoma.